Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was identified in Saudi Arabia in 2012. More than 1600 cases in 26 countries have been reported to date [1]. Many patients become critically ill, with a reported mortality of up to 70% among MERS CoV patients who require intensive care admission [2]. Hospital-based outbreaks have occurred mainly in the KSA. Outside of the KSA, South Korea experienced the second largest described outbreak. The outbreak, which originated from a single index case who had a history of travel to the Middle East, spread to several acute care facilities [3,4]. More recently, King Abdulaziz Medical City, Riyadh, Saudi Arabia, experienced a significant outbreak that led to the closure of the one of the largest tertiary care hospitals in the country, depriving thousands of patients of routine healthcare [5].

The continued threat and high mortality of MERS require continued collaborative research on the prevention and treatment of this disease. The majority of the burden of MERS is seen in Saudi Arabia. Hence, the Kingdom has led the design and conduct of national and international collaborative research for MERS, with the goal of identifying effective therapies that will benefit patients across the world. In the spirit of achieving these goals, the King Saud Bin Abdulaziz University for Health Sciences and the King Abdullah International Medical Research Center arranged the MERS research initiative workshop, which took place on September 9–10, 2015 in Riyadh, KSA. This workshop was in collaboration with the Ministry of National Guard Health Affairs, the Ministry of Health, the Saudi Food and Drug Authority and with national and international experts [6].

The meeting included a pre-conference solicitation of topics to be included and experts to attend, without distinction between governmental or non-governmental, organizational, academic, private or industry-affiliation participation. Identified individuals and organizations were invited to attend an open meeting in the spirit of broad collaboration to review the current state of knowledge, to identify gaps, and to identify the most promising and important research priorities to improve the care and outcomes of patients with MERS and to more broadly limit the impact of MERS on the population.

The two-day meeting was organized into three daily moderated sessions consisting of 20-min presentations by experts, followed by questions and a discussion of basic and translational sciences, diagnostics, epidemiology, infection prevention and control, drug and biologic therapeutics, research study design, funding opportunities, and regulatory considerations (Table 1). Industry and academic representatives who submitted proposals for specific potential therapeutics were invited to present...
privileged or proprietary information in a closed session to help inform attendees of promising and potential therapeutics to consider evaluating in clinical trials.

Both published and unpublished sources at the workshop identified knowledge gaps in the therapeutic and non-therapeutic aspects of MERS research [7]. Articles on selected topics that were presented at the workshop are included in this issue of the *Journal of Infection and Public Health*. Articles include a high-level perspective on the current status of drug development and clinical trials on MERS therapies and a description of the clinical spectrum of the presentation of MERS, both of which are critical for the design of clinical trials. In addition, an overview of drug development and necessary facilities is presented from the perspective of national animal and basic science health laboratories. Finally, selected promising products are explored, including LCA60 — human-derived monoclonal antibodies, nitazoxanide, and BCX4430 — a broad-spectrum antiviral adenosine nucleoside analog; we acknowledge that other therapeutics are at various stages of development and that new and emerging data require a continual re-evaluation of therapies with the most promise for evaluation. The intent of this workshop and the accompanying proceedings are to enhance the sharing of rapidly evolving basic and clinical sciences and a multidisciplinary early peer discussion and review to suggest priorities for ongoing MERS therapeutic research.

**Funding**

No funding sources.

**Competing interests**

None declared.

**Ethical approval**

Not required.

**References**


Yaseen M. Arabi (MD, FCCP, FCCM)\textsuperscript{a,b,*}  
\textsuperscript{a} Intensive Care Department, MC 1425, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia  
\textsuperscript{b} College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, Riyadh, Saudi Arabia  

Rob Fowler (MDCM, MS(Epi))\textsuperscript{a,b}  
\textsuperscript{a} University of Toronto, Department Medicine, Sunnybrook Health Sciences Centre, Canada  
\textsuperscript{b} University of Toronto, Department of Critical Care Medicine, Sunnybrook Health Sciences Centre, Canada  

Hanan H. Balkhy (MD, MMed, FAAP)\textsuperscript{a,b}  
\textsuperscript{a} Paediatric Infectious Diseases, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia  
\textsuperscript{b} Infection Prevention and Control, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia  

\textsuperscript{*} Corresponding author at: College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City, P.O. Box 22490, Riyadh 11426, Saudi Arabia.  
Tel.: +966 11 801111x18899/18855/18877;  
fax: +966 11 801111x18880.  
E-mail addresses: arabi@ngha.med.sa,  
icu1@ngha.med.sa (Y.M. Arabi),  
rob.fowler@sunnybrook.ca (R. Fowler),  
balkhyh@hotmail.com (H.H. Balkhy).